Jubilant Pharmova USFDA inspection: 8 observations (2026)

Key update from Spokane: inspection closed with 8 observations

Jubilant Pharmova said the US Food and Drug Administration (USFDA) has completed an inspection at its contract manufacturing facility in Spokane, Washington, operated through its subsidiary Jubilant HollisterStier LLC. The inspection concluded on June 17, 2026, and ended with eight observations from the regulator. The company highlighted that none of the observations are related to sterility assurance concerns. For a facility involved in sterile injectable and fill-finish activities, sterility assurance is a high-sensitivity area in regulatory reviews. The company said it intends to respond to the observations within 15 business days. It also stated that it remains committed to addressing the observations comprehensively.

What the company disclosed to stock exchanges

The update was disclosed by Jubilant Pharmova Limited to the exchanges in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The disclosure specifies that the inspection was conducted at Jubilant HollisterStier LLC (JHS), Spokane, WA, USA. It also states that the USFDA inspection has been concluded, which typically means the on-site portion of the audit is complete and the firm is now expected to respond to the cited items. Jubilant Pharmova reiterated the number of observations as eight. It further clarified that none of these observations pertain to sterility assurance concerns. The company’s stated timeline for its formal response is within 15 business days.

Why “no sterility assurance concerns” matters

The company’s emphasis on sterility assurance reflects the regulatory weight such issues can carry for sterile manufacturing operations. The provided information notes that sterility-related findings are considered among the most serious by regulators. Such concerns can lead to significant enforcement actions, including import bans or consent decrees, depending on severity and the regulator’s assessment. Against that context, Jubilant Pharmova’s statement that none of the eight observations relate to sterility assurance reduces the risk of immediate severe regulatory consequences based on the inspection close-out notes described. However, eight observations still require a detailed and timely response, and the next steps depend on the regulator’s review of corrective actions.

Next step: the 15-business-day response window

Jubilant Pharmova said it will respond to the USFDA’s observations within 15 business days. That response typically includes the company’s assessment of each observation, root-cause analysis, corrective actions already implemented, and preventive actions proposed, along with timelines and supporting documentation. The company has stated it will address the observations comprehensively. After the response is submitted, the USFDA reviews the firm’s corrective action plan and may seek clarifications or additional commitments. The company’s disclosure does not include the detailed content of the observations, only the count and the confirmation on sterility assurance.

What we know so far (inspection summary)

Recent regulatory context across Jubilant’s network

The Spokane update sits alongside other inspection-related disclosures and public updates referenced in the provided material. A separate item notes that a USFDA audit at the Spokane contract manufacturing facility ran from May 28 to June 6, 2024, and the inspection was classified as “Voluntary Action Indicated” (VAI), as per a stock exchange filing. The VAI classification, as described, indicates violations were observed but did not warrant further regulatory action, allowing the facility to continue operations, sell approved drugs, and receive approvals for new filings. The text also references a company press release dated Oct 28, 2024, stating Jubilant HollisterStier received zero observations from a USFDA inspection performed by the Center for Biologics Evaluation and Research, with inspectors reviewing manufacturing lines including a new sterile fill-finish line (Line 3) that is part of a $185 million facility expansion at Spokane. Additionally, the material references a USFDA inspection at a Montreal, Canada contract manufacturing facility that concluded on Nov 3, 2025, resulting in nine observations.

India facility reference: Roorkee PAI and observations

The provided material also mentions a USFDA pre-approval inspection (PAI) at the solid dosage formulations facility at Roorkee, India, of Jubilant Generics (a subsidiary structure within Jubilant’s group). That inspection concluded on Aug 1, 2025, and resulted in four observations. The company said it would submit an action plan on those observations. The disclosure also noted that the Roorkee site’s revenue from the US market in the trailing twelve months (July 2024 to June 2025) was less than one percent of Jubilant Pharmova revenues in the same period. While the Roorkee event is separate from Spokane, the reference indicates the group has been dealing with multiple regulatory touchpoints across geographies.

Longer-term history: 2013 warning letter reference

The material includes a historical reference to a USFDA warning letter issued in 2013 related to the Spokane facility. The text states that the company at the time said it would respond by or before December 12, 2013, and that the USFDA could withhold approval of new applications or supplements listing the Spokane site as a drug product manufacturer until corrections were completed and confirmed. It also noted the company’s expectation that ongoing manufacturing, distribution, and sale of products from the facility would not be impacted, while acknowledging the warning letter could affect new approvals. This historical point underscores why markets and customers tend to track inspection outcomes closely, particularly at sites involved in sterile and injectable operations.

Market impact and what investors typically watch next

This disclosure does not provide stock movement, financial impact, or product-level implications, so the immediate market read-through is primarily regulatory. The company’s statement that there were no sterility assurance concerns may ease near-term concern around the most severe categories of sterile-manufacturing enforcement risk, as described in the supplied material. But the presence of eight observations keeps attention on the quality system response and the timelines for corrective and preventive actions. Investors and customers typically monitor whether the company submits its response within the stated window and whether the regulator accepts the corrective action plan without escalation. The next concrete update, if any, would likely come through further regulatory correspondence or additional exchange disclosures tied to material developments.

Conclusion

Jubilant Pharmova’s Spokane facility inspection closed on June 17, 2026 with eight USFDA observations, and the company says none relate to sterility assurance concerns. Jubilant Pharmova has committed to responding within 15 business days under its disclosure obligations. The next milestone will be the submission of the formal response and the USFDA’s review of the corrective actions described by the company.